Company Growth (employees)
Karyopharm Therapeutics was founded in 2008 and is headquartered in Newton, US
Key People at Karyopharm Therapeutics
Michael Kauffman
Chief Executive Officer &Board of Directors
John McCartney
Senior Director, Product Leadership
Brian Austad
Vice President, Head of Pharmaceutical Sciences
Dilara McCauley
Vice President, Product Leadership
Karyopharm Therapeutics Office Locations
Karyopharm Therapeutics has offices in Newton and München
Newton, US (HQ)
85 Wells Ave
München, DE
9 Franziska Bilek Weg
Karyopharm Therapeutics Data and Metrics
Karyopharm Therapeutics Financial Metrics
Karyopharm Therapeutics's revenue was reported to be $250 k in FY, 2015 which is a 9% increase from the previous period.
Numbers are in $, USD
Revenue (FY, 2015) | 250 k |
Revenue growth (FY, 2014 - FY, 2015), % | 9% |
Net income (FY, 2015) | (118.2 m) |
EBIT (FY, 2015) | (119.1 m) |
Market capitalization (22-Jun-2017) | 469.3 m |
Closing share price (22-Jun-2017) | 9.5 |
Cash (31-Dec-2016) | 49.7 m |
Karyopharm Therapeutics's current market capitalization is $469.3 m.
- Source: SEC Filings
| Numbers are in $, USD | FY, 2013 | FY, 2014 | FY, 2015 |
|---|---|---|---|
Revenue | 387 k | 229 k | 250 k |
Revenue growth, % | (41%) | 9% | |
R&D expense | 28.5 m | 60.1 m | 97.7 m |
General and administrative expense | 5.9 m | 15.9 m | 21.6 m |
Operating expense total | 34.3 m | 76.1 m | 119.3 m |
EBIT | (34 m) | (75.8 m) | (119.1 m) |
EBIT margin, % | (8773%) | (33121%) | (47630%) |
Interest expense | 1 k | ||
Interest income | 3 k | 97 k | 897 k |
Net Income | (33.9 m) | (75.8 m) | (118.2 m) |
- Source: SEC Filings
| Numbers are in $, USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Cash | 156 m | 150.6 m | 58.4 m | 49.7 m |
Inventories | 2 m | 2 m | 2 m | 2.1 m |
Current Assets | 158 m | 207.8 m | 177.6 m | 131.6 m |
PP&E | 240 k | 2.8 m | 3.5 m | 2.8 m |
Total Assets | 158.2 m | 220.3 m | 215.4 m | 180.4 m |
Accounts Payable | 1.7 m | 6.3 m | 3.8 m | 4.8 m |
Current Liabilities | 3.3 m | 12.3 m | 15.1 m | 16.5 m |
Additional Paid-in Capital | 217.5 m | 345.2 m | 455.2 m | 528.6 m |
Retained Earnings | (138.3 m) | (256.5 m) | (366.1 m) | |
Total Equity | 154.9 m | 206.8 m | 198.4 m | 162.2 m |
Financial Leverage | 1 x | 1.1 x | 1.1 x | 1.1 x |
| Numbers are in $, USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Net Income | (33.9 m) | (75.8 m) | (118.2 m) | (109.6 m) |
Depreciation and Amortization | 144 k | 323 k | 634 k | 717 k |
Inventories | (1.4 m) | (45 k) | (55 k) | (120 k) |
Accounts Payable | 664 k | 4.5 m | (2.4 m) | 945 k |
Cash From Operating Activities | (30.3 m) | (51.4 m) | (94 m) | (84.4 m) |
Purchases of PP&E | (57 k) | (2.8 m) | (1.4 m) | (70 k) |
Cash From Investing Activities | (57 k) | (67 m) | (90.8 m) | 24.6 m |
Cash From Financing Activities | 185.9 m | 113.1 m | 92.7 m | 51.2 m |
| Y, 2016 | |
|---|---|
Financial Leverage | 1.1 x |
